Pss33 - Secukinumab as First Biologic Treatment: A Cost Per Responder Analysis Compared With Licensed Biologics, for Moderate to Severe Psoriasis in Argentina

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.2533
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Pss31 - Cost Per Responder of Secukinumab Compared to Other Biologics in Moderate-To-Severe Plaque Psoriasis From the Private Payer Perspective in Brazil

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Pss17 - Cost Per Responder Analysis of Brodalumab Compared With Ustekinumab in the Treatment of Moderate-To-Severe Plaque Psoriasis in Canada

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Cost Per Responder for Ixekizumab and Other Biologic Drugs Approved for the Treatment of Moderate-To-Severe Plaque Psoriasis in Italy

Global and Regional Health Technology Assessment
Health Policy
2019English

Pss16 - Cost Per Responder Analysis of Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam Versus Non-Biologic Systemic Therapy in the Treatment of Moderate to Severe Plaque Psoriasis

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Pss29 - Secukinumab Versus Etanercept for the Treatment of Psoriasis: A 52-Week Cost Per Responder Analysis From the Portuguese Payer Perspective

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Pss35 - Secukinumab Versus Ustekinumab for the Treatment of Psoriasis: A 52-Week Cost Per Responder Analysis From the Portuguese Payer Perspective

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

PSS14 Cost-Effectiveness of Biologic Therapies for the Treatment of Moderate to Severe Psoriasis in Germany

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2012English

Pms31 - Secukinumab as a More Eeficient Alternative for Ankylosing Spondylitis Treatment: A Cost Per Responder Analysis From Korean Perspective

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Psy103 - Modelling Average Cost and Cost-Per-Responder for Biological Treatments for Moderate-To-Severe Plaque Psoriasis With Dose Escalation and Real-World Drug Survival

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy